Organ | Type of constraint | Dose(Gy) for 3 fractions SBRT | Dose (Gy) for 5 fractions SBRT |
---|---|---|---|
Spinal cord | Dmax | 22 (7.33 Gy/fx) | 30 (6 Gy/fx) |
Esophagus | Dmax | 27 (9 Gy/fx) | 35 (7 Gy/fx) |
Trachea and main bronchi | Dmax | 30 (10 Gy/fx) | 32 (6.4 Gy/fx) |
Heart | Dmax | 30 (10 Gy/fx) | 38 (7.6 Gy/fx) |
Plexus brachialis | Dmax | 24 (8 Gy/fx) | 32 (6.4 Gy/fx) |
Ribs | Dmax | 37 (12.3/fx) | 43 (8.6/fx) |
Skin | Dmax | 32 (10.6/fx) | 24 (4.8/fx) |
Lung (both lungs) | Volumetric | V10.5Gy <1500 cc | V12.5Gy <1500 cc |
V11.4Gy <1000 cc | V13.5Gy <1000 cc | ||
Liver | Volumetric | V17.1Gy <700 cc | V21Gy <700 cc |
Radiotherapy scheme | BED10Gy(Gy) | n (%) |
---|---|---|
3×20 Gy | 180 | 96 (60%) |
3×18 Gy | 151.2 | 7 (4%) |
3×17 Gy | 137.7 | 4 (2.5%) |
5×12 Gy | 132 | 1 (0,6%) |
3×15 Gy | 112.5 | 24 (15%) |
5×10 Gy | 100 | 4 (2.5%) |
5×9 Gy | 85.5 | 11 (7%) |
5×8 Gy | 72 | 13 (8%) |
Study | Technic | Histological confirmation % | No. of pts/ lesions | dose (Gy)/fx | BED10Gy (Gray) | Median FUP (month) | Local Control | Overall Survival |
---|---|---|---|---|---|---|---|---|
PRIMARY | ||||||||
Chen VJ (26) | CK | 100 | 40 | median 48 (42-60)/3 fx | 124.8 | 44 | 91%@3y | 75%@3y |
van der Voort | CK | 51 | 70 | 60/3fx (Peripheral) | 180 (Peripheral) | 15 | 96%@2y for 60 Gy | 62%@2y |
van Zyp (27) | 45/3fx (Central) | 112.5 (Central) | 78%@2y for 45 Gy | |||||
Factor (28) | CK | 95 | 78 | 68/4 fx (Peripheral) | 75-180 | 14.4 | 87%@2y | 68%@2y |
48/4 fx (Central) | ||||||||
Bahig (4) | CK | 84 | 150 | median 60/3 fx | 72-180 (Peripheral) | 22 | 96%2y | 87%2y |
40-60/3-5 fx | 106-180 (Central) | |||||||
Shen (29) | CK | 84 | 50 | 57 (48-60)/3fx | 104-150 | 35 | crude 96%@2y | 86%@1y |
74%@2y | ||||||||
Davis, RSS REGISTRY (5) | CK,LINAC | 100 | 723/741 | median 54 (10-80)/3 fx | 151.2 | 12 | 88%@1y | T1: 85/63%@1/2y |
76%@2y | T2: 76/52@1y/2y | |||||||
Fakiris (30) | LINAC | 100 | 70 | 60-66/3fx | 180-211.2 | 50.2 | 88.1%@3y | 42.7%@3y |
Nuyttens (7) | CK | 12 | 30/57 | 30/1 fx; 60/3-5 fx; 56/7 fx | 36 | 79%@1y | 38%@2y | |
Inoue (8) | LINAC | 87/189 | 48/3fx; 50/5 fx; 52-60/10 fx; | 30-168 | 80%@2y | 47%@2y | ||
80%@3y | 32%%@3y | |||||||
Guckenberger (31) | LINAC | 19 | 124/159 | 26/1 fx; 37.5/3; 48/8 fx | 14 | 83%@3y | 37%@3y (Primary) | |
16%@3y (Met) | ||||||||
Ernst-Stecken (9) | LINAC | 100 | 21/39 | 35-40/5 fx | 59.5-72 | 6.3 | crude: 87% | crude: 86% |
84 (Peripheral) | 80.5%@2y | 52.7%@2y | ||||||
Duncker-Rohr (32) | LINAC | 55 | 39/45 | 37.5/3 fx; 30/5 fx | 60 (Central) | 17 | 95% @2y Prim | 45.9% (Primary) |
59.7%@2y Met | 66.7% (Met) | |||||||
total 61% | median 60/3 fx (Peripheral) | median 180 (Peripheral) | 86%@1y | |||||
Current study | CK | primary 77% | median 45/5 fx (Central) | median 112.5 (Central) | 21 | 75%@2y | ||
62 %@3y |
Characteristic | n (%) |
---|---|
Total number of patients/lesions | 130 (100%)/160 (100%) |
Mean age in years | 71 (range: 40–92) |
Male/female ratio | 77 (59%) / 53 (41%) |
No. with COPD | 45 (35%) |
Mean FEV1 (%) | 65 (range: 24–139) |
Mean FEV1 (L) | 2 (range: 0.53–3.65) |
Histological confirmation | 79 (61%) |
Primary cancer patients/lesions | 81 (62%) / 86 (54%) |
T1N0 | 53 |
T2N0 | 19 |
T3N0 | 5 |
T1N1 | 4 |
Recurrent tumor patients /lesions (n) | 23 (18%) / 35 (22%) |
Lung metastasis patients /lesions (n) | 26 (20%) / 39 (24%) |
Mean GTV volume (ml) | 11.5 (range: 0.6–86.5) |
Mean PTV volume (ml) | 33.2 (range: 5.8–118.1) |
Location of lesions: peripheral/central | 113 (71%) /47 (29%) |
Mean total dose (Gy)/Mean no. of fractions | 60/3 fx (range: 40–60 / 3–5 fx) |
Mean/median BED10Gy(Gy) | 151/180 Gy |